Insmed announces topline results from phase 1 study of treprostinil palmitil inhalation powder (tpip)

Bridgewater, n.j., feb. 19, 2021 /prnewswire/ -- insmed incorporated (nasdaq:insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced topline results from the phase 1 study of treprostinil palmitil inhalation...

INSM Ratings Summary

INSM Quant Ranking